Rapastinel - Allergan

Drug Profile

Rapastinel - Allergan

Alternative Names: BV-102; GLYX-13; GLYX-13-peptide; GLYX-13-trifluoroacetate; TPPT-amide; TPPT-amide-trifluoroacetate

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Northwestern University
  • Developer Allergan; Naurex
  • Class Amides; Antidepressants; Neuropsychotherapeutics; Oligopeptides; Small molecules
  • Mechanism of Action NR2B N-Methyl-D-Aspartate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Major depressive disorder
  • Discontinued Bipolar depression; Neuropathic pain

Most Recent Events

  • 18 Sep 2018 Naurex plans a phase III trial for Major depressive disorder (Monotherapy, Treatment-naive) in Hungary, Japan, Poland, Russia, Slovakia and Ukraine (IV) (NCT03675776) (JapicCTI-184134) (EudraCT2018-000060-29)
  • 03 Sep 2018 Phase-III clinical trials in Major depressive disorder (Monotherapy, Treatment-naive) in Ukraine, Slovakia, Russia, Poland, Hungary and Japan (IV) (JapicCTI-184134) (NCT03675776)
  • 23 Aug 2018 Naurex initiates a phase III trial for Major depressive disorder (Adjunctive treatment, Monotherapy) in USA (IV) (NCT03668600)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top